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Abstract: In December, 2010, Canada’s 6 year old Assisted Human Reproduction Act was 
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In 2004, the Parliament of Canada passed this nation’s Assisted Human Reproduc-
tion (AHR) Act,1 a piece of federal legislation that resulted, in part, from the lengthy 
Royal Commission on New Reproductive Technologies (RCNRT),2 which was struck 
to contextualize the new set of technologies within the milieu of Canadian values and 
concerns.
The AHR Act identified which specific practices were to be controlled and 
  prohibited in Canada and required the creation of a governmental agency, Assisted 
Human Reproduction Canada (AHRC), to monitor AHR practices and oversee enforce-
ment of the Act and its regulations. In addition, Health Canada created the Assisted 
Human Reproduction Implementation Office (AHRIO), to develop relevant regulations 
and associated policy. In accordance with the RCNRT’s recommendation, AHRC also 
began to explore the creation of a national AHR surveillance system.
After a challenge from Quebec to the AHR Act’s constitutionality, the Supreme 
Court of Canada ruled3 in December of 2010 that many aspects of the AHR Act were 
unconstitutional. As summarized by Baylis,4 the legal issue before the Court was 
whether the “pith and substance” of the contested sections of the AHR Act were:
1.  to protect morality, safety, and public health; and
2.  to regulate and promote the benefits of medical practice and research related to 
assisted human reproduction.
According to the Constitution Act of 1867,5 the first component above is a federal 
matter, while the second is a provincial matter. In general, the Supreme Court decided 
that Ottawa was within its right to pass legislation regarding criminality, for instance 
in the banning of human cloning; but that the right to regulate clinics and clinicians 
remains the purview of the provinces. This paper presents some reflections on the 
possible implications of the ruling on public health, the philosophy of health care and 
health policy in Canada, and on the disposition of our AHR industry.
AHR is relevant to the discussion of the evolution of health care in Canada for at 
least two reasons. First, given its inclusion of philosophies pertaining to life, death, 
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with, and attitudes toward, AHR ultimately reflects its core 
values. And second, in Canada, AHR is one of those rare 
medical realms, along with such things as laser eye surgery, 
dental care and various laboratory services, which includes 
a privatized stratum. Thus, it is a vanguard for the prob-
able expansion of medical privatization within Canada’s 
  socialized system.
With the initial passing of the Act, Canada joined a small 
group of nations which have enacted federal legislation 
relating to AHR. The USA has failed to establish a national 
regulatory framework, and given the likelihood of cross-
border care between Canada and the USA, it is interesting 
to consider the extent to which the Americans’ decentralized 
regulatory system influenced the evolution of the Canadian 
case. Merchant6 believes that the key difference between 
the USA and nations with federal AHR regulations (such as 
Canada and many European nations) is that the latter tend to 
formally consider health to be a human right, contrary to the 
individualistic American approach. According to some, the 
development of Canada’s AHR legal and ethical framework 
has indeed been influenced by our proximity to the USA.7 
Does the diminishing of Canada’s federal framework, then, 
indicate a retreat from an ethic of considering health within a 
rights-based philosophy? More defensibly, such a retreat may 
signal a larger trend toward the decentralization of measures 
to adjudicate the marriage of medicine with commerce.
The creation of Canada’s AHR policy was the result of 
disparate, often conflicting forces. In addition to Canada’s 
proximity to the USA, Jones and Salter7 identified “feminist-
informed activism”, the power and influence of professional 
clinical bodies, and of course Canada’s famous federal-
provincial jurisdictional challenges as being key vectors 
in forming the AHR Act. The constitutional challenge to 
the Act was, of course, the result of our federal-provincial 
power struggles. But enactment of the elements that remain 
after the Supreme Court ruling may still be subject to the 
influences of the other forces described by Jones and Salter.7 
In other words, the Act was born from conflict, its challenge 
was yet another stage of that conflict, and it is likely that 
conflict will continue to surround and define it until another 
concerted national effort is made to consolidate and elucidate 
  Canadians’ attitudes toward assisted reproduction.
Clearly, the formation of legislation and policy around 
AHR is complicated by inputs from a vast array of seemingly 
unrelated viewpoints and perspectives, many of which ulti-
mately speak to core societal values. (And while these view-
points have some commonalities globally, the key influencers 
are most definitely culture-specific: the forces forging AHR 
policy in Europe and the USA, for instance, will not   necessarily 
be the same forces at play in Canada.) Any changes to sweep-
ing federal legislation will necessarily impact the same wide 
array of stakeholders in this country to varying degrees, and 
not just the immediate clinical players.
In this paper, we suggest that the likely impacts of the 
Supreme Court’s revisiting of the AHR Act that are most rel-
evant to public health are the potential creation of a domestic 
reproduction tourism industry and the probable slowing of 
the creation of a national ART surveillance system.
Among the values-based foci of the Act was the crimi-
nalization of payment for gametes, embryos, reproductive 
material, and surrogacy. This scenario was likely a contributor 
to the global reproductive tourism industry, wherein Western 
clients would travel to less developed countries, such as 
India, to offer money for such services as ovum purchasing 
or surrogacy on demand. In India alone, the reproductive 
tourism industry is now worth between $500 million8 and 
$2.3 billion9 annually.
Controlled and prohibited activities that the Supreme 
Court did not find unconstitutional will remain homogenously 
enforced across the country. But certain controlled activi-
ties have been struck from the legislation, and individual 
provinces can now choose whether to legislate in these 
areas. As a result of the Supreme Court decision, aspects of 
the disposition of human reproductive tissue are no longer 
a federal   matter, but a provincial one. Provinces and territo-
ries can choose to regulate activities, such as the storing or 
transportation of in vitro embryos, but may choose not to. 
This presents the possibility of a heterogeneous domestic 
landscape of regulation, with respect to certain practices.
Baylis identified the number of embryos transferred per 
IVF cycle as an area in which there will likely be diversity 
across provinces,4 correctly identifying heterogeneity in 
this matter as both an ethical and health concern. In absence 
of legislation on this matter, or at the very least stringently 
followed professional guidelines, there may be a tendency 
for economic considerations to fill the legislative void. 
A client may argue strongly for a multiple embryo transfer, 
for instance, to minimize the number of cycles she expects 
to fund before a successful live birth, while adopting the 
increased medical risk that such a choice embodies. This 
is the scenario that gave rise to California’s “Octo-Mom,” 
Nadya Suleman, who chose to dangerously carry eight 
embryos to term, due in large part to her inability to pay for 
many more cycles.10 It is that sort of situation that Baylis 
alluded to when characterizing the regulatory scenario prior 
to the AHR Act as one born of a “Wild West culture.”4International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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If intra-Canadian heterogeneity in legislation on these 
key practices does indeed become the norm, the prospect 
then arises of a domestic reproductive tourism industry, with 
service seekers traveling a gradient from more restrictive 
provinces to less restrictive ones. The likelihood of such a 
domestic market arising in a meaningful fashion is balanced 
against the realities of global economics. Well-established 
reproductive tourism services in developing countries like 
India are able to offer high quality services for dramatically 
lower prices than can be offered in wealthier nations. The 
gradient that drives the international industry is largely con-
sidered to be an economic one, which would likely trump a 
domestic gradient, which would also likely be based more 
upon regulatory rigour without offering significant cost 
advantages, due to Canada’s federal ban on payment for 
gametes and surrogacy, which has not been affected by the 
Supreme Court’s decision.
The anticipated smallness of such a domestic fertility 
tourism market, relative to the international one, might 
change if less restrictive provinces were to experience 
organized investments in infrastructure relevant to the ease 
of provision of reproductive services to visitors, much like 
the state-level investments made in India to help grow that 
country’s medical tourism industry. It will be interesting to 
see how the Canadian ART industry re-organizes itself in 
coming months to potentially exploit such a domestic mar-
ket, perhaps initially in the form of ART clinics pursuing 
greater connections with extra-provincial physicians who 
might refer clientele.
From a population health perspective, of most immediate 
concern is the disposition of the RCNRT’s recommendation 
to establish a national surveillance system for AHR. With 
the probable diminishing of the scope of AHRC’s mandate, 
the agency’s leadership in creating a true federal surveillance 
system may also diminish. Such a system is required for three 
main reasons. First, due to anonymous gamete donation from 
a shrinking pool of donors, there is a non-trivial likelihood 
of half siblings living in close proximity to one another. In 
2007, the media reported on a donor who may have fathered 
as many as 50 children in his region.11 His is not a unique 
story in the lay media. The threat of unconscious consanguine 
coupling is therefore real. Surveillance is a viable strategy 
for mitigating (though certainly not eliminating) the risk of 
such couplings, depending upon the extent of collection of 
personal donor information.
Second, assisted reproductive technologies can be 
considered a vector for disease.12 Both infectious and 
inherited diseases can be transmitted through the gamete 
donation process.12 Surveillance is the least expensive and 
most efficient method for detecting disease clusters that may 
be caused by AHR, and potentially for tracing their sources, 
again depending upon the extent of collection of personal 
information.
Third, despite being in common usage for over three 
decades, AHR is still a set of very new technologies. Many 
long term and multigenerational health outcomes have yet to 
be assessed in a systematic fashion.13 Surveillance presents 
the opportunity to detect and study previously unidentified 
outcomes that may affect public health, refinement of the 
technologies, and the perspectives of policymakers.
The inability of Canada’s federal agencies’ to mandate 
participation in a national AHR surveillance system is con-
cerning because the political and resource barriers faced by 
individual provinces to create such a system are significant. 
A viable approach might be for Ottawa to lead the coordination 
and provide funding for a multi-provincial system.
The history of AHR suggests that the technologies’ evolu-
tion will steer society in new directions. Our legal, ethical, 
philosophical and clinical perspectives will shift in response. 
The recent change to Canada’s federal regulatory framework 
is but one manifestation of this shift. The coming months will 
reveal the first signs of the new face of AHR in this country. 
And while those participating in the reproductive services 
phenomenon still constitute a relatively small proportion of 
Canadians seeking medical services, the manner in which a 
society chooses to conceptualize and regulate its reproductive 
technology services will ultimately reflect a population’s core 
values and philosophies, thus making this issue a socially 
and politically preponderant one.
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